


AN EVENING PROGRAM AT ROCKEFELLER**TRANSLATIONAL RESEARCH:
HOW THE DRUG PIPELINE WORKS****Date:** Tuesday, January 23, 2007**Time:** 6:00 – 7:00 p.m., Program
7:00 – 8:00 p.m., Reception**Place:** Abby Aldrich Rockefeller HallThe Rockefeller University
York Avenue at East 66th Street

Over the past decade, a new generation of precisely targeted drugs has begun to emerge, based on a growing knowledge of specific molecular defects that lead to disease. The revolution in biomedical understanding that has made these drugs possible holds promise for many more breakthroughs in the years ahead.

While the opportunities in “rational drug design” are unprecedented, the challenges of bringing new medications to market are formidable. A drug’s journey from the research lab through clinical trials and onto pharmacy shelves is usually long, arduous, and expensive—costing hundreds of millions of dollars and taking an average of 12 years. In 2005, the Food and Drug Administration approved only 20 innovative drugs—so-called new molecular entities—for use in the United States. What are the ingredients of successful drug development, and how can translational research facilitate the process?

On Tuesday, January 23, a special evening program on translational research and the “drug pipeline” will feature Dr. Barry Collier, who is noted for his role in developing the commercial drug abciximab. Known by the trade name Reo-Pro, abciximab is used worldwide to reduce complications of coronary artery angioplasty and stent placement. More than two million people have been treated with this drug since 1994, when it was approved by the FDA.



Barry S. Collier, M.D., *Physician-in-Chief, David Rockefeller Professor, Head, Allen and Frances Adler Laboratory of Blood and Vascular Biology*, joined The Rockefeller University in 2001 as vice president for medical affairs and physician-in-chief of The Rockefeller University Hospital. Recently, with his leadership, the University became one of the first twelve U.S. research institutions to receive a prestigious new clinical award funded by the National Institutes of Health. This award, which carries with it a \$45 million grant to Rockefeller, is designed to transform clinical and translational research so that novel treatments can be developed more efficiently and delivered more quickly to patients.

A specialist in vascular biology and blood disorders, Dr. Collier serves on the NIH Advisory Board for Clinical Research. He has been elected to the National Academy of Sciences and the Institute of Medicine, and among his many other honors are the American Heart Association National Research Award and the Pasarow Award. In 1997, Dr. Collier was named the New York Intellectual Property Law Association’s Inventor of the Year.

For more information please call Joanna Kondratowicz
at (212) 327-7168, or by e-mail at ruc@rockefeller.edu